Unlock instant, AI-driven research and patent intelligence for your innovation.

Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer

A technology of antiviral agents and inhibitors, which is applied in the field of reducing or reducing tumors, can solve the problems that have not been raised, increase the sensitivity of tumor cells to EGFR inhibition, and achieve the effect of enhancing EGFR blocking

Inactive Publication Date: 2013-01-30
INSTITUT GUSTAVE ROUSSY +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] It is also believed that the prior art does not suggest that antiviral agents enhance EGFR blockade induced by EGFR inhibitors, and more particularly antiviral agents eliminate or alleviate drug resistance and / or increase the sensitivity of tumor cells to EGFR inhibition

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
  • Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
  • Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0329] Embodiment 1: in vitro test

[0330] Substances and methods

[0331] cell culture medium :

[0332] Cell lines were obtained from the American Type Culture Collection (ATCC):

[0333] -HeLa cells (human HPV positive cervical cancer cells): ATCC n°CCL-2;

[0334] -Me180 cells (human HPV positive cervical cancer cells): ATCC n°'TB-33;

[0335] - C33A cells (human HPV negative cervical cancer cells): ATCC n°TB-31.

[0336] - H460 cells (human HPV negative lung cancer cells): ATCC n°'HTB-177.

[0337] HeLa cells contained 0.11g / L sodium pyruvate and 4.5g / L glucose Dulbecco's Modified Eagle's Medium (obtained from Invitrogen with catalog reference number 31966021 DMEM) supplemented with 10% fetal calf serum (FCS), 1% penicillin / streptomycin and 1% glutamine.

[0338] HeLa cells contain 10-50 copies of integrated HPV18.

[0339] Me180 cells in Grown in McCoy 5A medium (obtained from Invitrogen as catalog reference number 26600023) supplemented with 10% FCS, ...

Embodiment 2

[0447] Example 2: In Vivo Test (Mice)

[0448] Substances and methods

[0449] Materials and methods are those described in Example 1 above, unless otherwise specified. In vivo experiments were performed at the Institut Gustave Roussy (94805 Villejuif; France) with the approval of the French Ministry of Agriculture.

[0450] Female nude mice were from January hatches (CERT 53940, le Geneset St Isle, France). 10- to 12-week-old female nude mice were subcutaneously injected (into the flank) with 2 × 10 6 Live HeLa cells to study tumor growth. Once the tumor reaches 5mm 2 , cidofovir (100mg / mouse) was injected intraperitoneally for five days (days 1, 2, 3, 4, 5) and cetuximab was injected intraperitoneally (1 mg / mouse) for three days (1st, 4th, 7th day). Tumor volume and weight were monitored twice weekly. Mice were sacrificed when tumors reached ten times their initial volume.

[0451] Results and discussion:

[0452] The first injection of the drug in mice resul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The application relates to a combination of biologically active compounds comprising at least one antiviral agent and at least one EGFR antagonist, for simultaneous, separate or sequential use in the treatment and / or prevention and / or palliation of malignant or pre-malignant neoplasms, preferably of solid malignant or pre-malignant neoplasms.

Description

field of invention [0001] The present invention relates in particular to EGFR inhibitors and antiviral agents for simultaneous, separate or sequential use in the treatment and / or prevention and / or alleviation of tumors, more particularly malignant or premalignant tumors, still more particularly cancer, and to Combination preparations comprising at least one EGFR inhibitor and at least one antiviral agent and their pharmaceutical and biotechnological uses, more particularly for the treatment and / or prevention and / or alleviation of tumors, more particularly malignant or premalignant The field of neoplasms, still more particularly cancers. Background of the invention [0002] Epidermal growth factor receptor (EGFR) is one of the molecules that has been proven to be an important target for cancer therapy. In its association with poor survival, EGFR is prominently expressed at high levels in many tumors including squamous cell carcinoma of the head and neck (SCCHN), cervical, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/675A61K45/06A61K31/517A61K31/522A61K31/662A61K39/395A61P35/00
CPCA61K31/675A61K39/39558A61K31/662A61K39/3955A61K31/517A61K31/522A61K45/06A61P35/00A61K2300/00
Inventor 埃里克·德意志玛丽·凯瑟琳·沃兹宁让·博里斯
Owner INSTITUT GUSTAVE ROUSSY